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Abstract
: Extended-spectrum beta-lactamase producingBackground
Enterobacteriaceae (ESBL-E) threaten human health; and, in areas of
sub-Saharan Africa (sSA) where carbapenems are not available, may
render ESBL-E infections untreatable. Gut mucosal colonisation probably
occurs before infection, making prevention of colonisation an attractive
target for intervention, but the epidemiology of ESBL-E in sSA is poorly
described.
: Describe ESBL-E colonisation prevalence in sSA and riskObjectives
factors associated with colonisation.
 Studies included were prospective cross-sectional or cohortMethods:
studies reporting gut mucosal ESBL-E colonisation in any population in
sSA. We searched PubMed and Scopus on 18 December 2018. We
summarise the range of prevalence across sites and tabulated risk factors
for colonisation. The protocol was registered (Prospero ID 
).CRD42019123559
 From 2975 abstracts we identified 32 studies including a total ofResults:
8619 participants from a range of countries and settings. Six studies were
longitudinal; no longitudinal studies followed patients beyond hospital
discharge.  Prevalence varied between 5 and 84% with a median of 31%,
with a relationship to setting: pooled ESBL-E colonisation in community
studies was 18% (95% CI 12 to 28, 12 studies); in studies recruiting people
at admission to hospital colonisation was 32% (95% CI 24 to 41% 8
studies); and for inpatients, colonisation was 55% (95% CI 49 to 60%, 7
studies). Antimicrobial use was associated with increased risk of ESBL-E
colonisation, and protected water sources or water treatment by boiling
may reduce risk.
 ESBL-E colonisation is common in sSA, but how peopleConclusions:
become carriers and why is not well understood. To inform the design of
interventions to interrupt transmission in this setting requires longitudinal,
community studies.
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Introduction
Extended-spectrum beta-lactamase producing Enterobacte-
riaceae (ESBL-E) are a significant threat to human health, and 
have been identified by the World Health Organisation as patho-
gens of critical importance1. In sub-Saharan Africa (sSA), it 
is increasingly clear that a significant proportion of invasive 
Enterobacteriaceae infections are ESBL-E and the absence 
of second line antimicrobials can render infections with these 
pathogens locally untreatable2. Strategies to interrupt ESBL-E 
transmission that can be practically deployed at scale in 
low resource settings are urgently needed.
Gut mucosal colonisation with Enterobacteriaceae is thought 
to precede invasive infection3,4, and so preventing ESBL-E 
colonisation is an attractive strategy for prevention of invasive 
disease. Data describing the basic epidemiology of ESBL-E 
colonisation in sSA, will help inform the design of interven-
tions targeted at reducing colonisation. A 2016 meta-analysis 
of community ESBL-E colonisation prevalence among healthy 
individuals found only four studies from sSA with a pooled 
prevalence of 15% (95% CI 4–31%), and significant between-
study heterogeneity5. No studies described risk factors from 
Africa. We were aware of a number of studies that had been 
published since 2016 including a number that described ESBL-
E colonisation in any population, so undertook a systematic 
review and meta-analysis with two aims: firstly, to describe the 
prevalence of ESBL-E gut mucosal colonisation in sSA; and 
secondly, to describe any risk factors associated with colo-
nisation. In terms of the PRISMA (preferred reporting 
items for systematic reviews and meta analyses) PICOS 
(participants, interventions, comparisons, outcomes and study 
design) approach, our questions can be framed as: what is the 
prevalence of ESBL-E gut mucosal colonisation (the out-
come) and risk factors for colonisation (comparisons) in any 
population in sSA (the population) as measured in prospective 
cross-sectional or cohort studies (study design).
Methods
Inclusion criteria were any prospective cross-sectional or 
cohort study that had screened for gut mucosal colonisation 
of ESBL-E in any population in sSA for which it was possible 
to extract a numerator and denominator to calculate an 
ESBL-E colonisation prevalence. Exclusion criteria were stud-
ies in which the sampled population was not clearly defined 
in a reproducible way (i.e. laboratory-based studies), or if the 
laboratory techniques aimed to isolate only a particular organ-
ism or type of organism (e.g. Enteropathogenic E. coli). 
PubMed and Scopus were searched in all fields using the 
search terms given in Table 1, on 18 December 2018. Abstracts 
were extracted into Endnote X7.8 (Thomson Reuters, United 
States) and independently reviewed against the inclusion 
criteria by two authors (JL and RL), with disagreements settled 
by consensus. 
Full-text review of included studies was then undertaken, with 
studies assessed against the same inclusion criteria, again with 
disagreements settled by consensus. Data were then extracted 
into a Microsoft Excel for Mac v16.27 spreadsheet (Micro-
soft, United States): study title and authors, year of publication, 
dates of sample collection, inclusion criteria, median age or par-
ticipants, details of microbiologic testing procedures, number 
of participants and number of participants from whom ESBL-
E were isolated, and any risk factors for ESBL-E that were 
assessed and/or found to be associated with ESBL-E colonisa-
tion. Two authors extracted data independently (RL and JL) and 
any inconsistencies corrected by re-review of the original paper. 
For cohort studies only the baseline prevalence was included. 
Prevalence was presented as forest plots with exact binomial con-
fidence intervals. Age group (neonate, child, adult, as per study 
definition) and location of sampling (community, outpatient 
[including health centre attendees], on hospital admission, 
[defined as a hospital inpatient for < 24hr] hospitalised, [defined as 
a hospital inpatient for > 24hr]) were selected as a priori 
subgroups that we hypothesised may explain heterogeneity 
in ESBL-E prevalence, and analyses were stratified by these 
subgroups. Studies were additionally classified as being carried 
out in a special population if they were carried out in a sub-
population of a subgroup (for example, pregnant women 
in the community). Effect size of risk factors for ESBL-E 
colonisation were presented as odds ratios; if odds ratios 
were not provided by the original studies then they were 
calculated, with 0.5 added to zero cells. Pooled random effect 
summary estimates of prevalence, where calculated, were gener-
ated using the metaprop package in R using the inverse variance 
method with a logit transformation. All analysis was undertaken 
using R v3.5.1 (R Foundation for Statistical Computing, 
Vienna, Austria).
Risk of bias of included studies was assessed with a modi-
fied Critical Appraisal Skills Programme (CASP) checklist, 
designed to fit our research question (full tool available as 
extended data). The risk of bias assessment was performed 
by JL and RL, and any disagreements were resolved by 
consensus.
Table 1. Systematic review search terms.
((ESBL) OR Extended-spectrum beta-lactamase)) AND (((Angola OR Benin OR Botswana OR Burkina Faso OR Burundi OR 
Cameroon OR Cape Verde OR Central African Republic OR Chad OR Comoros OR Republic of the Congo OR Congo Brazzaville 
OR Democratic republic of the Congo OR Cote d’Ivoire OR Djibouti OR Equatorial Guinea OR Eritrea OR Ethiopia OR Gabon OR 
The Gambia OR Ghana OR Guinea OR Guinea-Bissau OR Kenya OR Lesotho OR Liberia OR Madagascar OR Malawi OR Mali OR 
Mauritania OR Mauritius OR Mozambique OR Namibia OR Niger OR Nigeria OR Reunion OR Rwanda OR Sao Tome and Principe 
OR Senegal OR Seychelles OR Sierra Leone OR Somalia OR South Africa OR Sudan OR Swaziland OR Eswatini OR Tanzania OR 
Togo OR Uganda OR Western Sahara OR Zambia OR Zimbabwe) OR Africa))
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The protocol of this review was published on PROSPERO 
(PROSPERO ID CRD42019123559) and the review was under-
taken as per Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) guidelines (PRISMA checklist 
available Reporting guidelines).
Results
Of 2975 identified unique studies, 32 were included in this 
review6–37 (Figure 1), from 19 countries in sSA (Table 2). Stud-
ies from three countries – Tanzania (n=7), Madagascar (n=4) and 
Cameroon (n=4) - together made up 15/32 (47%) of the available 
studies. In total, 8619 participants were included and for 
7232/8619 (84%) it was possible to disaggregate the participants 
into age groups: 4313/7232 (60%) were adults, 2470/7232 (34%) 
children and 449/7232 (6%) neonates. 2302/8619 (27%) of 
included participants were community members, 1729/8619 
(20%) were outpatients, 2836/8619 (33%) were sampled on 
admission to hospital, and 1534/8619 (18%) were inpatients. 
6/32 studies were cohort studies; all of these studies followed 
patients up whilst hospitalised only. Many studies were carried 
out in special populations, including the majority of community 
studies: 9/12 community studies were in special populations, 
as well as 3/7 outpatient studies, 3/8 studies of participants 
on hospital admission and 2/7 inpatient studies. It was not 
possible to classify patients from two studies into our prede-
fined categories: one sampled staff and children of an orphanage, 
and the other hospital workers and their families. These 
studies were excluded from the pooled analyses. Details of the 
microbiological testing procedures are shown in Table 3.
The results of the risk of bias assessment are shown in 
Figure 2. The most notable potential for biased ESBL-E preva-
lence estimates resulted from selection of study populations. 
Several studies recruited a selected group, which we defined as a 
special population: pregnant women, street children, children 
and staff of an orphanage, or food handlers in schools. These are 
likely to produce a biased estimate of community prevalence. 
Though microbiological culture methods were frequently 
described in a reproducible manner, few studies reported quality 
control procedures, resulting in an assessment of moderate risk 
of bias for the majority of studies across this domain.
Overall ESBL-E colonisation prevalence was extremely hetero-
geneous across studies ranging from 5–84% (median 31%) with 
no trend by year of publication (Figure 3). Some heterogeneity 
was explained by location of sampling (Figure 4): inpatients 
tended to have the highest colonisation prevalence with 
community members the least. There was no clear difference 
in prevalence between neonates, children or adults (Figure 5). 
Pooled random-effect summary estimates were therefore calcu-
lated for differing location of sampling: community members 
(18% [95% CI 11–28%]), outpatients (23% [95% CI 13-39%]), 
inpatients on hospital admission (32% [95% CI 24–41%]) and 
inpatients (55% [95% CI 49-60%]), though in each stratum 
significant heterogeneity remained (I2 76–97%) so these 
summary estimates should be treated with caution (Figure 4).
Two-thirds (21/32) of studies performed an analysis to iden-
tify factors associated with ESBL-E colonisation (Table 4). 
Prior hospitalisation was assessed as a risk factor in 13 stud-
ies, and a statistically significant association found in 4/13, with 
odds ratios of 2.1-8.5. Antimicrobial exposure was assessed in 
13 studies, and a statistically significant association found in 
5/13 with odds ratios of 1.6-27.0. Using water from a borehole28, 
boiling water before drinking14 and having private inside access 
to drinking water10 were found to be associated with a lower 
prevalence of ESBL-E colonisation in three different stud-
ies. One study found that a higher socio-economic status was 
Figure 1. Flow chart of included studies.
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Table 2. Details of included studies. CAR = Central African Republic; ART = antiretroviral therapy; UTI = urinary tract infection; NR = not 
reported. yr = year; m = months, d = days, hr = hours. * = mean rather than media.
Study Year Pub.
Study 
Period Country
Study 
Type
Inclusion 
Population: details
Age 
group
Median 
age n
COMMUNITY STUDIES
Albrechtova 2012 2012 2009 Kenya Cross sec. General population Adults NR 23
Mshana 2016 2016 2014 Tanzania Cross sec. General population both 10yr 334
Katakweba 2018 2018 2011–13 Tanzania Cross sec. General population Adults NR 70
Ruppe 2009 2009 NR Senegal Cross sec. Special population (remote villages) Children 6.9yr* 20
Lonchel 2012 2012 2009 Cameroon Cross sec. Special population (students) Adults 24.7yr* 150
Chereau 2015 2015 2013–14 Madagascar Cross sec. Special population (pregnant women) Adults 26yr* 356
Farra 2016 2016 2013 CAR Cross sec. Special population (healthy controls in a diarrhoea study) Children 10.5m 134
Ribeiro 2016 2016 2013 Angola Cross sec. Special population (no antibiotics/hospital exposure last 3 mo) Adults NR
Tellevik 2016 2016 2010–11 Tanzania Cross sec. Special population: <2yr attending health centre for vaccine Children NR 250
Moremi 2017 2017 2015 Tanzania Cross sec. Special population (street children) Children 14.2yr* 107
Chirindze 2018 2018 2016 Mozambique Cross sec. Special population (Students in the community) Adults NR 275
Sanneh 2018 2018 2015 The Gambia Cross sec. Special population (Food handlers in schools) Adults 37yr* 565
HOSPITAL OUTPATIENTS
Herindrainy 2011 2011 2009 Madagascar Cross sec. Outpatients Adults NR 306
Lonchel 2012 2012 2009 Cameroon Cross sec. Outpatients Adults 36.9yr* 208
Magoue 2013 2013 2010 Cameroon Cross sec. Outpatients Adults NR 232
Outpatients Children NR 147
Djuikoue 2016 2016 2011–12 Cameroon Cross sec. Special population (outpatient women with susp. UTI) Adults NR 86
Wilmore 2017 2017 2014–15 Zimbabwe Cross sec. Special population (outpatient, HIV infected, stable on ART) Children 11yr 175
Herindrainy 2018 2018 2015–16 Madagascar Cross sec. Special population (Pregnant women at delivery) Adults 26yr* 275
Stanley 2018 2018 2017 Uganda Cross sec.
Special population (participants who reared 
animals, attending health facility with a fever 
and/or diarrhoea but without malaria)
both 21.7yr* 300
ON HOSPITAL ADMISSION
Andriatahina 2010 2010 2008 Madagascar Cohort On hospital admission Children 38.3m 244
Kurz 2016 2016 2014 Rwanda Cohort On hospital admission both 29yr 753
Magwenzi 2017 2017 2015 Zimbabwe Cohort On hospital admission Children 1.0yr 164
Founou 2018 2018 2017 South Africa Cohort On hospital admission Adults NR 43
Moremi 2018 2018 2014–15 Tanzania Cohort On hospital admission Adults NR 930
Woerther 2011 2011 2007–08 Niger Cohort Special population (Children with SAM) Children 16.3m* 55
Isendahl 2012 2012 2010 Guinea-Bissau Cross sec.
Special population (Children att. hospital w/ 
fever or tachycardia) Children NR 408
Nelson 2014 2014 2013 Tanzania Cohort Special population (Pregnant women and 
neonates, inpatient)
Neonate 0d 126
Adults 26.5yr* 113
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Table 3. Details of microbiologic testing procedures. NR = not reported; API = analytical profile index; MALDI-TOF = 
Matrix-Assisted Laser Desorption/Ionization-Time of Flight.
Study Sample type Screening method
Speciation 
method
ESBL confirmation 
method
Ruppe 2009 Stool Drigalski and chromagar NR Double disc
Tande 2009 Stool Drigalski with cephalosporin API Double disc
Andriatahina 2010 Rectal Swab Drigalski with cephalosporin API Double disc
Herindrainy 2011 Stool Drigalski with cephalosporin API Double disc
Woerther 2011 Stool Chromagar API PCR
Albrechtova 2012 Rectal Swab Mackonkey with cephalosporin API Double disc
Isendahl 2012 Rectal Swab Chromagar Vitek Vitek
Lonchel 2012 Stool Mackonkey or Drigalski and cephalosporin MALDI-TOF Double disc
Lonchel 2013 Stool Mackonkey or Drigalski and cephalosporin MALDI-TOF Double disc
Magoue 2013 Stool Mackonkey or Drigalski and cephalosporin NR Double disc
Schaumburg 2013 Rectal Swab Chromagar Vitek Double disc
Nelson 2014 Rectal Swab Mackonkey with cephalosporin Biochemical Double disc
Chereau 2015 Stool Drigalski with cephalosporin API Double disc
Desta 2016 Stool Chromagar Vitek Vitek
Djuikoue 2016 Stool Drigalski with cephalosporin MALDI-TOF Double disc
Farra 2016 Stool Chromagar NR Double disc
Kurz 2016 Rectal Swab Chromagar API Combination disc
Mshana 2016 Stool Mackonkey with cephalosporin API Chromagar and vitek
Ribeiro 2016 Stool Chromagar MALDI-TOF PCR
Tellevik, 2016 Stool Chromagar MALDI-TOF Combination disc
Study Year Pub.
Study 
Period Country
Study 
Type
Inclusion 
Population: details
Age 
group
Median 
age n
INPATIENTS
Lonchel 2013 2013 2009 Cameroon Cross sec. Inpatients Adults 46.8yr* 121
Magoue 2013 2013 2010 Cameroon Cross sec. Inpatients Adults NR 208
Schaumburg 
2013 2013 2010–11 Gabon Cross sec. Inpatients Children NR 200
Desta 2016 2016 2012 Ethiopia Cross sec. Inpatients Adults 35yr 154
Inpatients Children 7yr 94
Inpatients Neonate 9d 19
Tellevik 2016 2016 2010–11 Tanzania Cross sec. Inpatients Children NR 353
Nikema 
Pessinaba 2018 2018 2015–16 Togo Cross sec.
Special population (<5yr with febrile 
gastroenteritis) Children NR 81
Marando 2018 2018 2016 Tanzania Cross sec. Special population (Neonates with sepsis) Neonate 6d 304
OTHER
Tande 2009 2009 2003 Mali Cross sec. Orphanage children Children NR 38
Orphanage staff Adults NR 30
Magoue 2013 2013 2010 Cameroon Cross sec. Hospital workers and their families Adults NR 87
Relatives and carers of inpatients Adults NR 63
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Study Sample type Screening method
Speciation 
method
ESBL confirmation 
method
Magwenzi 2017
Stool or 
Rectal Swab
Chromagar and Mackonkey with cephalosporin 
and nutrient broth with cephalosporin API Double disc
Moremi 2017 Stool Mackonkey with cephalosporin Biochemical Double disc
Wilmore 2017 Stool CLEDwith cephalosproin
API and 
MALDI Combination disc
Chirindze 2018 Stool Mackonkey with cephalosporin API Double disc
Founou 2018 Rectal Swab Mackonkey with cephalosporin API Combination disc
Herindrainy 2018
Stool or 
Rectal Swab Chromagar MALDI-TOF Double disc
Katakweba 2018 Stool Mackonkey with cephalosporin MALDI-TOF Double disc
Marando 2018 Rectal swab Mackonkey with cephalosporin Biochemical Double disc
Moremi 2018 Rectal swab Mackonkey with cephalosporin vitek vitek
Nikema Pessinaba 
2018 Stool Drigalski with cephalosporin NR NR
Sanneh 2018 Stool Drigalski And Cephalosporin NR Double disc
Stanley 2018 Stool AST BD phoenix BD phoenix
Figure 2. Results of risk of bias assessment. Domain 1: Are the characteristics of the participants included in the study adequately 
described? Domain 2: Are the eligibility criteria to enter the study explicit and appropriate? Domain 3: Were stool culture results precise and 
reported? Domain 4: Were the methods of extended-spectrum beta-lactamase (ESBL) confirmatory testing precise?
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Figure 3. Overall extended-spectrum beta-lactamase producing Enterobacteriaceae (ESBL-E) colonization prevalence by study.
associated with a lower ESBL-E prevalence29, and one the 
opposite13. Only two studies addressed the association between 
HIV status and ESBL-E colonisation status; one, in adults found 
no association9, whereas the other, in children, found a strong 
association17. Only one study assessed the association between 
animals in the home as ESBL-E colonisation10, finding no 
association.
Of the 6 cohort studies, all sampled participants on admis-
sion to hospital and on discharge, a median 5.6-8 days later, 
and all found an increase in ESBL-E colonisation prevalence 
between the two sampling points (Table 5). No study longitu-
dinally sampled ESBL colonisation in the community, either in 
community dwellers or in those discharged from hospital.
Discussion
ESBL-E colonisation is common across sSA, though with 
significant unexplained heterogeneity between study loca-
tions and populations. Community ESBL-E colonisation ranges 
from 5% in adults in Gambia in 2015 to 59% in children in the 
Central African Republic in 2013, the latter comparable to the 
highest described colonisation prevalence in the world5. Our 
pooled estimate suggests 18% (95% CI 11–29%) of people in sSA 
are colonised with ESBL-E, a higher prevalence than in high 
income settings. In Europe, community prevalence of ESBL-
E colonisation is reported to range from 3.7% in Spain in 2004 
to 7.3% in the UK in 201438–41, similar to the United States 
where a community prevalence of 3.4% was reported in healthy 
children42. In many of the estimates of studies included in 
this review, the reported prevalence of ESBL-E is more 
comparable to that reported in Asia (46% [95% CI 29–63%]5).
The profound differences in community ESBL-E colonisation 
prevalence between sSA and high-resource settings warrants 
further investigation, beyond the assessment of risk factors we 
have identified in this review. Hospitalisation and antimicrobial 
use are likely drivers of colonisation in the studies, with higher 
prevalence seen in hospitalised individuals and prior hospi-
talisation and antimicrobial exposure frequently identified 
as risk factors for colonisation. Obversely and consistent with 
a putative faecal-oral transmission route, use of borehole water, 
a private indoor water source and boiling water before drinking 
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Figure 4. Extended-spectrum beta-lactamase (ESBL) colonisation by study with pooled random effect summary estimates stratified 
by location of sampling. ESBL prop. = proportion of ESBL producing Enterobacteriaceae.
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Figure 5. Extended-spectrum beta-lactamase producing Enterobacteriaceae (ESBL-E) carriage prevalence stratified by age group.
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Table 4. Assessed and significant risk factors in the included studies. mv = multivariate, uv = univariate, HH = household, abx = 
antibiotics, SES = socio-economic status, HC = health centre, ART = antiretroviral therapy, VL = viral load, PROM = premature rupture 
of membranes, WASH = water, sanitation and hygiene. UTI = urinary tract infection, NR = not reported. * confidence interval crosses 1; 
original publication used fisher’s exact test and found p < 0.05.
Study Risk factors assessed Analysis Significant risk factors Odds ratio (95% CI)
Tande 2009 Adults with direct contact with the children in orphanage uv Contact with orphanage children 19.7 (3.2 - 201.3)
Andriatahina 
2010
Age, gender, patient origin (home vs health 
facility), abx or hospitalisation last 30days, 
admitting dx, infection on admission
mv Hospitalisation last 30d 7.4 (2.9-18.3)
Herindrainy 2011 SES, no. of rooms occupied, ratio occupants:room mv
Occupation HH head unemployed 
vs manager 9.1 (1.6-53.9) 
Isendahl 2012 Age, gender, weight, MUAC, breastfeeding, bedsharing, children in HH, abx, hospitalisation uv Bedsharing 1.9 (1.0 - 3.4)
Lonchel 2013 Age, gender, hospital, diagnosis, abx within 3m, hospitalisation within 1yr mv
Hospitalisation during the previous 
year 4.13 (1.37–12.78)
Admission with infection 0.30 (0.10–0.82)
Intermediate vs tertiary hospital 4.10 (1.77–9.59)
Schaumburg 
2013
Age, hospitalisation, residence, sex, diagnosis, 
abx use mv
Age <=5 2.2 (1.1–4.8)
Hospitalization 5–7 days vs < 5 5.1 (1.6–18.4)
Hospitalization for =7 days vs < 5 30.6 (5.8–566.0)
Hospital stay during the past  
12 months 2.1 (1.1–4.0)
Nelson 2014
For neonates: Gestation, birthweight, gender, 
delivery method, ward, abx use
uv
Antibiotic use 10.8 (0.6 - 186)*
For mothers: Delivery mode, admission within 
30d, abx within 3m, abx within 30d, current 
abx, catheter, HIV status
Nothing
Chereau 2015
Study area, age, education, marital status, 
type house, electricity, type of birth attendant, 
toilets, water, animals at home, hospitalisation, 
abx use
mv Private inside access to drinking water 0.3 (0.1–0.8)
Desta 2016
Higher maximum bed capacity per room, 
increasing number of patients admitted in 
single room
uv Sharing room vs not 4.0 (2.3 to 5.3)
Djuikoue 2016 Age, pregnancy, abx last 3m, hospital last 3m uv None
Farra 2016
Age, gender, comorbidity, SES, nutritional 
status, animals at home, toilets, urban/rural, hh 
members, meals
mv Highest SES class vs lowest 31.06 (2.49–387.13)
Kurz 2016
Age, gender , residence, ward, referral, other 
healthcare 3m, abx 3m, education, SES, water 
source, food, time to HC, caregiver ESBL 
status
mv
ESBL colonised caregiver, 2.88 (1.80-4.61)
Antibiotics within 3 months, 2.70 (1.59-4.58)
Frequently consume eggs 6.52 (1.75-24.31)
Boil water prior to drinking 0.59 (0.37-0.92)
Mshana 2016 Age, region, no of children in house, abx use within 1m, admission within 1yr mv
Older age (per yr), 1.07 (1.04–1.10) 
Hospital admission last yr 7.4 (1.43–38.5)
Abx last 3m 27 (6.63–116),
Tellevik, 2016
Age, gender, residence, parental education, 
child group, nutritional status, use of abx within 
14 days
mv
HIV vs no HIV, 9.99 (2.52–39.57),
Kinondoni district, 2.62 (1.49–4.60)
Abx last 14d 1.61 (1.07–2.41)
Moremi 2017 Age, education, herb use, source of income, source of food, street child type mv
Local herb use, 3.3 (1.31–8.31), 
Sleep on streets vs not 2.8 (1.04–7.65)
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Study Risk factors assessed Analysis Significant risk factors Odds ratio (95% CI)
Wilmore 2017
Age, gender, CD4, VL, ART duration, admitted 
to hospital with pneumonia in last 12m, adm to 
hospital in at 12 m
mv
ART <1yr 8.47 (2.22–2.27)
Admission with pneumonia in last 
12m 8.47 (1.12–64.07)
Marando 2018 Age, gender, weight, admission where, clinical factors, abx use, PROM mv
Current abx use 1.73 (1.00-2.97), 
ESBL colonised mother 2.19 (1.26-3.79)
Moremi 2018 Age, gender, history of antibiotic use, history of admission, history of surgery mv Older age (per year) 1.01 (1.00–1.02)
Nikema 
Pessinaba 2018
Age, gender, site, drinking water source, time 
to sample analysis mv
Drink non borehole water vs 
borehole 3.47 (1.22-9.82) 
Sanneh 2018
WASH behaviours, hospitalised within 3m, 
invasive procedures, abx within 3m, abx from 
street, completing abx, diarrhoea/UTI 3m, food 
handling training
uv
Lack of food handling training and 
knowledge of the principle of food 
safety 
NR
Abx within 3m NR
Stanley 
2018 Age, gender, health facility, presentation uv none
Table 5. Longitudinal ESBL prevalence in included cohort studies. NR = not reported.  
* = median not given but admission length was 2–10 days.
Study Study population
ESBL prevalence
Median follow up
Admission Discharge
Andriatahina 2010 Children 51/244 (21%) 88/154 (57%) 5.7d
Woerther 2011 Children 17/55 (31%) 15/16 (94%) 8d
Nelson 2014 Neonates 32/126 (25%) 77/126 (61%) 7d
Kurz 2016 Adults and children 195/392 (50%) 173/208 (83%) 6d
Magwenzi 2017 Children 86/164 (52%) 115/164 (70%) 5.6d
Moremi 2018 Adults 220/930 (24%) 143/272 (53%) NR*
were associated with reduced ESBL-E colonisation risk, and 
it may be that poor water, sanitation and hygiene (WASH) 
infrastructure and practices in sSA are driving high ESBL-E 
colonisation prevalence. This speaks to a role for poverty in 
driving ESBL-E colonisation; however, this is likely complex, 
and context-dependant, as evidenced by conflicting findings 
of the effect of socio-economic status on colonisation from 
two studies in different settings.
More broadly, this review highlights areas where data that 
could inform interventions to interrupt ESBL-E transmission 
are lacking. In the community, long-term longitudinal ESBL-E 
colonisation studies are necessary to understand the dynamics 
of community ESBL-E transmission, particularly the role of 
within household transmission, and the role of household ani-
mals. In health facilities, the determinants of apparent ESBL-E 
acquisition need to be clearly identified to design pragmatic 
intervention studies in the context of limited resources. Surpris-
ingly, the role of HIV in driving the high ESBL-E colonisation 
prevalence in sSA is unknown. HIV is known to pro-
foundly affect gut function, but we identified only two studies 
which have assessed HIV status as a risk factor for ESBL-E 
colonisation.
There are limitations of our review. Our search strategy may 
have missed studies that would otherwise be included. How-
ever, using broader inclusion criteria than a recent review of 
worldwide ESBL-E community colonisation prevalence5, we 
have identified many more studies from sSA. Risk of bias 
assessment in observational studies is difficult, with no gold 
standard, and the tool we have used may misclassify studies 
with regard to bias. Significant heterogeneity remaining despite 
stratification warrants caution in interpreting summary estimates.
In conclusion, ESBL-E colonisation in sSA is common, and 
in places comparable to the highest prevalence in the world, 
though with significant unexplained heterogeneity between coun-
tries and populations. Hospitalisation, antimicrobial use, and 
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poor WASH infrastructure and practices may be contributing 
to high prevalence; the roles of HIV and animal-human trans-
mission remain unknown. Given the threat to human health of 
ESBL-E, data to fully characterise routes and drivers of trans-
mission in sSA are necessary to design interventions to 
interrupt transmission in this setting.
Data availability
Underlying data
All data underlying the results are available as part of the article 
and no additional source data are required.
Extended data
Zenodo: Risk of bias tool and PRISMA checklist used for the 
publication: Gut mucosal colonisation with extended-spectrum 
beta-lactamase producing Enterobacteriaceae in sub-Saharan 
Africa: a systematic review and meta-analysis, http://doi.
org/10.5281/zenodo.347827843
This project contains the following extended data:
-    Risk of bias tool used in the study
Reporting guidelines
Zenodo: PRISMA checklist for: Gut mucosal colonisation 
with extended-spectrum beta-lactamase producing Entero-
bacteriaceae in sub-Saharan Africa: a systematic review and 
meta-analysis, http://doi.org/10.5281/zenodo.347827843.
Data are available under the terms of the Creative Commons 
Attribution 4.0 International license (CC-BY 4.0).
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Extended spectrum beta-lactamase (ESBL) producing enteric pathogens are a major cause of
hospitalization and mortality in sub-Saharan Africa (SSA), more so because alternative options for
effective treatment of infections are either too expensive to afford or are completely unavailable in these
settings. I believe this review is timely as it provides information on the extent to which data from the
region could provide insight into the extent of gut mucosal colonization (a precursor for invasive disease
when immune-suppression may happen) and ensure that we institute policies that effectively reduce
colonization and control of infections in these settings. 
The authors observed a rather disturbing trend in data spread across the continent as only a meager 32
studies could qualify to have had data on gut colonization and ESBL testing done. Indeed only 6 of these
studies followed up patients beyond the hospital discharge. The authors observed that antimicrobial use
was associated with increased risk of ESBL-E colonization, and protected water sources or water
treatment by boiling may reduce risk in affected patients.
The authors did their best to review all available data to answer their key review questions. The
methodology was robust and systematic, and the analysis is complex but easy to follow. The major
weakness in this review (which is really non-methodological) is the small number of studies available for
the large population of SSA and for which major conclusions to be drawn from such a small sample size
would be greatly flawed. There is no doubt that gut mucosal colonization with ESBL-producing gut
pathogens plays a major role as a risk factor for invasive disease in hospitalized patients, this has been
shown in studies in other parts of the world and such evidence is therefore crucial to compare with SSA.
The poor implementation of WaSH in communities and Infection Prevention and control (IPC) strategies in
healthcare settings certainly add to the challenges associated with prevention of gut-associated mucosal
colonization with ESBL-producing bacteria. It is crucial that the authors clearly indicate the major flaw with
the conclusion especially as it is based on a rather small and thinly spread number of studies in SSA.
Although HIV and the role of livestock transmission of these zoonotic pathogens in studies in SSA was
inconclusive, the fact that the studies reviewed may not necessarily have had these as study objectives
cannot be ruled out. Interpretation of such review data should be therefore done with caution especially
pertaining to possible key risk factors in disease transmission and gut colonization.
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